Diagnosing and preventing iron overload

Hemodialysis International

Volumn 21, Issue , 2017, Pages S58-S67

  Ramanathan, Ganesh ^a   Olynyk, John K ^b,c,d,e   Ferrari, Paolo ^a,f  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b FIONA STANLEY HOSPITAL   (Australia)

^c MURDOCH UNIVERSITY   (Australia)

^d CURTIN UNIVERSITY   (Australia)

^e EDITH COWAN UNIVERSITY   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

anemia; End stage kidney disease; ferritin; hemoglobin; iron; liver; MRI

Indexed keywords

HEMOGLOBIN; HEPCIDIN; IRON; TRANSFERRIN; FERRITIN;

ANEMIA; CARDIOVASCULAR RISK; ERYTHROPOIESIS; FERRITIN BLOOD LEVEL; GENE EXPRESSION; HEMODIALYSIS; IRON DEFICIENCY; IRON METABOLISM; IRON OVERLOAD; LIVER BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; REVIEW; BLOOD; HUMAN; KIDNEY DISEASE; LIVER; METABOLISM;

FERRITINS; HUMANS; IRON; IRON OVERLOAD; KIDNEY DISEASES; LIVER; MAGNETIC RESONANCE IMAGING; RENAL DIALYSIS;

EID: 85017163039     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/hdi.12555     Document Type: Review

References (93)

1. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987; 316:73–78.
2. Kalantar-Zadeh K, Lee GH, Miller JE, et al. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis. 2009; 53:823–834.
3. Mallick S, Rafiroiu A, Kanthety R, Iqbal S, Malik R, Rahman M. Factors predicting erythropoietin resistance among maintenance hemodialysis patients. Blood Purif. 2012; 33:238–244.
4. Carter RA, Hawkins JB, Robinson BH. Iron metabolism in the anaemia of chronic renal failure. Effects of dialysis and of parenteral iron. Br Med J. 1969; 3:206–210.
5. Milman N. Iron absorption measured by whole body counting and the relation to marrow iron stores in chronic uremia. Clin Nephrol. 1982; 17:77–81.
6. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant. 2004; 19:141–149.
7. Fishbane S, Pollack S, Feldman HI, Joffe MM. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. Clin J Am Soc Nephrol. 2009; 4:57–61.
8. Kuragano T, Shimonaka Y, Kida A, et al. Determinants of hepcidin in patients on maintenance hemodialysis: Role of inflammation. Am J Nephrol. 2010; 31:534–540.
9. Young B, Zaritsky J. Hepcidin for clinicians. Clin J Am Soc Nephrol. 2009; 4:1384–1387.
10. Zaritsky J, Young B, Wang HJ, et al. Hepcidin – A potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol. 2009; 4:1051–1056.
11. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006; 47:S11–S145.
12. Macginley R, Walker R, Irving M. KHA-CARI guideline: Use of iron in chronic kidney disease patients. Nephrology. 2013; 18:747–749.
13. Macdougall IC, Bircher AJ, Eckardt KU, et al. Iron management in chronic kidney disease: Conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2016; 89:28–39.
14. Charytan C, Qunibi W, Bailie GR. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract. 2005; 100:c55–c62.
15. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. 2012; 2:279–335.
16. Himmelfarb J. Iron regulation. J Am Soc Nephrol. 2007; 18:379–381.
17. Hegsted DM. The recommended dietary allowances for iron. Am J Public Health Nations Health. 1970; 60:653–658.
18. De Domenico I, Ward DM, Kaplan J. Hepcidin regulation: Ironing out the details. J Clin Invest. 2007; 117:1755–1758.
19. Graham RM, Chua AC, Herbison CE, Olynyk JK, Trinder D. Liver iron transport. World J Gastroenterol. 2007; 13:4725–4736.
20. Chua AC, Graham RM, Trinder D, Olynyk JK. The regulation of cellular iron metabolism. Crit Rev Clin Lab Sci. 2007; 44:413–459.
21. Rishi G, Wallace DF, Subramaniam VN. Hepcidin: Regulation of the master iron regulator. Biosci Rep. 2015; 35:e00192.
22. Olynyk JK, Trinder D, Ramm GA, Britton RS, Bacon BR. Hereditary hemochromatosis in the post-HFE era. Hepatology. 2008; 48:991–1001.
23. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014; 46:678–684.
24. Peters HP, Laarakkers CM, Swinkels DW, Wetzels JF. Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate. Nephrol Dial Transplant. 2010; 25:848–853.
25. Kroot JJ, Tjalsma H, Fleming RE, Swinkels DW. Hepcidin in human iron disorders: Diagnostic implications. Clin Chem. 2011; 57:1650–1669.
26. Tsukamoto T, Matsubara T, Akashi Y, Kondo M, Yanagita M. Annual iron loss associated with hemodialysis. Am J Nephrol. 2016; 43:32–38.
27. Wizemann V, Buddensiek P, de Boor J, Grebe S, Schutterle G. Gastrointestinal blood loss in patients undergoing maintenance dialysis. Kidney Int Suppl. 1983; 16:S218–S220.
28. Sargent JA, Acchiardo SR. Iron requirements in hemodialysis. Blood Purif. 2004; 22:112–123.
29. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996; 50:1694–1699.
30. Taylor JE, Peat N, Porter C, Morgan AG. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant. 1996; 11:1079–1083.
31. Locatelli F, Barany P, Covic A, et al. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: A European Renal Best Practice position statement. Nephrol Dial Transplant. 2013; 28:1346–1359.
32. Albaramki J, Hodson EM, Craig JC, Webster AC. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev. 2012; 1:Cd007857.
33. Kliger AS, Foley RN, Goldfarb DS, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. Am J Kidney Dis. 2013; 62:849–859.
34. Ratcliffe LE, Thomas W, Glen J, et al. Diagnosis and Management of iron deficiency in CKD: A summary of the NICE guideline recommendations and their rationale. Am J Kidney Dis. 2016; 67:548–558.
35. Ali M, Fayemi AO, Rigolosi R, Frascino J, Marsden T, Malcolm D. Hemosiderosis in hemodialysis patients. An autopsy study of 50 cases. JAMA. 1980; 244:343–345.
36. Gokal R, Millard PR, Weatherall DJ, Callender ST, Ledingham JG, Oliver DO. Iron metabolism in haemodialysis patients. A study of the management of iron therapy and overload. Q J Med. 1979; 48:369–391.
37. Pitts TO, Barbour GL. Hemosiderosis secondary to chronic parenteral iron therapy in maintenance hemodialysis patients. Nephron. 1978; 22:316–321.
38. Hakim RM, Stivelman JC, Schulman G, et al. Iron overload and mobilization in long-term hemodialysis patients. Am J Kidney Dis. 1987; 10:293–299.
39. Kalantar-Zadeh K, Lee GH. The fascinating but deceptive ferritin: To measure it or not to measure it in chronic kidney disease?. Clin J Am Soc Nephrol. 2006; 1:S9–S18.
40. Murray MJ, Murray AB, Murray MB, Murray CJ. The adverse effect of iron repletion on the course of certain infections. Br Med J. 1978; 2:1113–1115.
41. Seifert A, von Herrath D, Schaefer K. Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis. Q J Med. 1987; 65:1015–1024.
42. Bregman H, Gelfand MC. Iron overload in patients on maintenance hemodialysis. Int J Artif Organs. 1981; 4:56–57.
43. Drueke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002; 106:2212–2217.
44. Fishbane S, Jhaveri KD. The new label for erythropoiesis stimulating agents: The FDA'S sentence. Semin Dial. 2012; 25:263–266.
45. Pisoni RL, Fuller DS, Bieber BA, Gillespie BW, Robinson BM. The DOPPS practice monitor for US dialysis care: Trends through August 2011. Am J Kidney Dis. 2012; 60:160–165.
46. Bailie GR, Larkina M, Goodkin DA, et al. Variation in intravenous iron use internationally and over time: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2013; 28:2570–2579.
47. Del Vecchio L, Longhi S, Locatelli F. Safety concerns about intravenous iron therapy in patients with chronic kidney disease. Clin Kidney J. 2016; 9:260–267.
48. Winchester JF. Management of iron overload in dialysis patients. Semin Nephrol. 1986; 6:22–26.
49. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol. 2005; 16:3070–3080.
50. Singh AK, Coyne DW, Shapiro W, Rizkala AR, Group DS. Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int. 2007; 71:1163–1171.
51. Ferrari P, Kulkarni H, Dheda S, et al. Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol. 2011; 6:77–83.
52. Canavese C, Bergamo D, Ciccone G, et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int. 2004; 65:1091–1098.
53. Rostoker G, Griuncelli M, Loridon C, et al. Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: A MRI study. Am J Med. 2012; 125:991–999.e1.
54. Ghoti H, Rachmilewitz EA, Simon-Lopez R, et al. Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol. 2012; 89:87–93.
55. Holman R, Olynyk JK, Kulkarni H, Ferrari P. Characterisation of hepatic and cardiac iron deposition during standard treatment of anaemia in haemodialysis. Nephrology (Carlton). 2017; 22:114–117.
56. Kuo KL, Hung SC, Lin YP, et al. Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and increased cardiovascular risk among hemodialysis patients. PLoS One. 2012; 7:e50295.
57. Kuragano T, Matsumura O, Matsuda A, et al. Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients. Kidney Int. 2014; 86:845–854.
58. Bailie GR, Larkina M, Goodkin DA, et al. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int. 2015; 87:162–168.
59. Fishbane S, Mathew A, Vaziri ND. Iron toxicity: Relevance for dialysis patients. Nephrol Dial Transplant. 2014; 29:255–259.
60. Gaenzer H, Marschang P, Sturm W, et al. Association between increased iron stores and impaired endothelial function in patients with hereditary hemochromatosis. J Am Coll Cardiol. 2002; 40:2189–2194.
61. Reis KA, Guz G, Ozdemir H, et al. Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease. Int Heart J. 2005; 46:255–264.
62. Sullivan JL. Iron in arterial plaque: Modifiable risk factor for atherosclerosis. Biochim Biophys Acta. 2009; 1790:718–723.
63. Kautz L, Gabayan V, Wang X, et al. Testing the iron hypothesis in a mouse model of atherosclerosis. Cell Rep. 2013; 5:1436–1442.
64. Kshirsagar AV, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Brookhart MA. Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients. PLoS One. 2013; 8:e78930.
65. Dauros-Singorenko P, Swift S. The transition from iron starvation to iron sufficiency as an important step in the progression of infection. Sci Prog. 2014; 97:371–382.
66. Muench KH. Hemochromatosis and infection: Alcohol and iron, oysters and sepsis. Am J Med. 1989; 87:40n–43n.
67. Avni T, Bieber A, Grossman A, Green H, Leibovici L, Gafter-Gvili A. The safety of intravenous iron preparations: Systematic review and meta-analysis. Mayo Clin Proc. 2015; 90:12–23.
68. Ishida JH, Marafino BJ, McCulloch CE, et al. Receipt of intravenous iron and clinical outcomes among hemodialysis patients hospitalized for infection. Clin J Am Soc Nephrol. 2015; 10:1799–1805.
69. Barany P, Eriksson LC, Hultcrantz R, Pettersson E, Bergstrom J. Serum ferritin and tissue iron in anemic dialysis patients. Miner Electrolyte Metab. 1997; 23:273
70. Kaufman JS, Reda DJ, Fye CL, et al. Diagnostic value of iron indices in hemodialysis patients receiving epoetin. Kidney Int. 2001; 60:300–308.
71. Wish JB. Assessing iron status: Beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol. 2006; 1:S4–S8.
72. Ali M, Rigolosi R, Fayemi AO, Braun EV, Frascino J, Singer R. Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy. Lancet. 1982; 1:652–655.
73. Fusaro M, Munaretto G, Spinello M, et al. Soluble transferrin receptors and reticulocyte hemoglobin concentration in the assessment of iron deficiency in hemodialysis patients. J Nephrol. 2005; 18:72–79.
74. Fishbane S, Galgano C, Langley RC Jr, Canfield W, Maesaka JK. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int. 1997; 52:217–222.
75. Jones CH, Richardson D, Ayers S, Newstead CG, Will EJ, Davison AM. Percentage hypochromic red cells and the response to intravenous iron therapy in anaemic haemodialysis patients. Nephrol Dial Transplant. 1998; 13:2873–2876.
76. Kurzawa T, Owczarek A, Strzelczyk JK, Golabek K, Wiczkowski A. The content of reticulocyte hemoglobin and serum concentration of the soluble transferrin receptor for diagnostics of anemia in chronically hemodialyzed patients. Adv Clin Exp Med. 2016; 25:425–431.
77. Chiang WC, Tsai TJ, Chen YM, Lin SL, Hsieh BS. Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients. Clin Nephrol. 2002; 58:363–369.
78. Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med. 2000; 343:327–331.
79. Papakonstantinou OG, Maris TG, Kostaridou V, et al. Assessment of liver iron overload by T2-quantitative magnetic resonance imaging: Correlation of T2-QMRI measurements with serum ferritin concentration and histologic grading of siderosis. Magn Reson Imaging. 1995; 13:967–977.
80. Clark PR, St Pierre TG. Quantitative mapping of transverse relaxivity (1/T(2)) in hepatic iron overload: A single spin-echo imaging methodology. Magn Reson Imaging. 2000; 18:431–438.
81. Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005; 106:1460–1465.
82. St Pierre TG, Clark PR, Chua-Anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005; 105:855–861.
83. Nielsen P, Engelhardt R, Dullmann J, Fischer R. Non-invasive liver iron quantification by SQUID-biosusceptometry and serum ferritin iron as new diagnostic parameters in hereditary hemochromatosis. Blood Cells Mol Dis. 2002; 29:451–458.
84. Alustiza JM, Castiella A, De Juan MD, Emparanza JI, Artetxe J, Uranga M. Iron overload in the liver diagnostic and quantification. Eur J Radiol. 2007; 61:499–506.
85. St Pierre TG, Clark PR, Chua-Anusorn W. Single spin-echo proton transverse relaxometry of iron-loaded liver. NMR Biomed. 2004; 17:446–458.
86. Gandon Y, Olivie D, Guyader D, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004; 363:357–362.
87. Hankins JS, McCarville MB, Loeffler RB, et al. R2* magnetic resonance imaging of the liver in patients with iron overload. Blood. 2009; 113:4853–4855.
88. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994; 331:567–573.
89. Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology. 1986; 6:24–29.
90. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997; 89:739–761.
91. Olynyk JK, St Pierre TG, Britton RS, Brunt EM, Bacon BR. Duration of hepatic iron exposure increases the risk of significant fibrosis in hereditary hemochromatosis: A new role for magnetic resonance imaging. Am J Gastroenterology. 2005; 100:837–841.
92. Fletcher LM, Dixon JL, Purdie DM, Powell LW, Crawford DH. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology. 2002; 122:281–289.
93. Green D, Roberts PR, New DI, Kalra PA. Sudden cardiac death in hemodialysis patients: An in-depth review. Am J Kidney Dis. 2011; 57:921–929.